Abstract
Obesity has been associated with both the carcinogenesis and poor prognosis of colon cancer, one of the leading causes of cancer-related death. Increased blood levels of insulin in obese subjects have been demonstrated to play a key role in carcinogenesis. It is also possible that insulin affects treatment efficacy, leading to poor prognosis. In this study, we demonstrated that insulin can increase HT29 colon cancer cell line resistance to cycloheximide and 5- fluorouracil induced cytotoxicity. This effect can be inhibited by the PI3K/Akt inhibitor Ly294002, indicating the important role of this pathway in the insulin-induced inefficacy of chemotherapy. The insulin-induced resistance to cycloheximide and 5-fluorouracil can be used in drug screening to overcome the inefficacy of chemotherapy in obesity-associated colon cancer.
Keywords: Insulin, PI3K/Akt pathway, cycloheximide, 5-fluorouracil, cytotoxicity, Ly294002, obesity, HT29 cells, colon cancer
Current Drug Discovery Technologies
Title: Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway
Volume: 8 Issue: 2
Author(s): Jiezhong Chen, Andrew Katsifis, Changhua Hu and Xu-Feng Huang
Affiliation:
Keywords: Insulin, PI3K/Akt pathway, cycloheximide, 5-fluorouracil, cytotoxicity, Ly294002, obesity, HT29 cells, colon cancer
Abstract: Obesity has been associated with both the carcinogenesis and poor prognosis of colon cancer, one of the leading causes of cancer-related death. Increased blood levels of insulin in obese subjects have been demonstrated to play a key role in carcinogenesis. It is also possible that insulin affects treatment efficacy, leading to poor prognosis. In this study, we demonstrated that insulin can increase HT29 colon cancer cell line resistance to cycloheximide and 5- fluorouracil induced cytotoxicity. This effect can be inhibited by the PI3K/Akt inhibitor Ly294002, indicating the important role of this pathway in the insulin-induced inefficacy of chemotherapy. The insulin-induced resistance to cycloheximide and 5-fluorouracil can be used in drug screening to overcome the inefficacy of chemotherapy in obesity-associated colon cancer.
Export Options
About this article
Cite this article as:
Chen Jiezhong, Katsifis Andrew, Hu Changhua and Huang Xu-Feng, Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway, Current Drug Discovery Technologies 2011; 8 (2) . https://dx.doi.org/10.2174/157016311795563820
DOI https://dx.doi.org/10.2174/157016311795563820 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Phosphocitrate, A Potential Therapeutic Agent for Calcium Crystal Deposition Diseases
Current Rheumatology Reviews Radiolabeled Nanoparticles, Angionesis and Therapeutics of Cancer Researches Together With Preclinical Models
Current Radiopharmaceuticals Literature Review: Use of Family History for Primary Paediatric Care as the Next Step Towards use of Genomics in Healthcare
Current Pediatric Reviews Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Review on Documented Medicinal Plants used for the Treatment of Cancer
Current Traditional Medicine Tubulins as Therapeutic Targets in Cancer: from Bench to Bedside
Current Pharmaceutical Design Nanoemulsion: A Novel Eon in Cancer Chemotherapy
Mini-Reviews in Medicinal Chemistry Biosurfactants as a Novel Additive in Pharmaceutical Formulations: Current Trends and Future Implications
Current Drug Metabolism Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Patent Selections
Recent Patents on Anti-Cancer Drug Discovery The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes
Current Clinical Pharmacology Restoration of Transgene Expression in Hematopoietic Cells with Drug-Selectable Marker Genes
Current Gene Therapy Recent Advances in Herbal Nanomedicines for Cancer Treatment
Current Molecular Pharmacology Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design QSAR Guided Semi-synthesis and <i>In-Vitro</i> Validation of Anticancer Activity in Ursolic Acid Derivatives
Current Topics in Medicinal Chemistry Vascular Endothelial Growth Factor: Adaptive Changes in the Neuroglialvascular Unit
Current Neurovascular Research Open Access High Throughput Drug Discovery in the Public Domain: A Mount Everest in the Making
Current Pharmaceutical Biotechnology Recent Advances on Radionuclide Labeled Hypoxia-Imaging Agents
Current Pharmaceutical Design The Cytoprotective and Anti-cancer Potential of Bisbenzylisoquinoline Alkaloids from <I>Nelumbo nucifera</I>
Current Topics in Medicinal Chemistry